Sardana Kabir, Kaur Ravinder, Arora Pooja, Goyal Ritu, Ghunawat Sneha
Department of Dermatology, Dr. Ram Manohar Lohia Hospital and PGIMER, New Delhi, India.
Department of Microbiology, Lady Hardinge Medical College, New Delhi, India.
Indian Dermatol Online J. 2018 Mar-Apr;9(2):90-95. doi: 10.4103/idoj.IDOJ_137_17.
Dermatophytoses are one of the most common skin diseases that have been largely simple to treat. However, in recent years, these infections have become recalcitrant to treatment which can possibly be due to antifungal resistance.
To analyze the resistance pattern of patients with recalcitrant dermatophytoses.
A cross-sectional evaluation was undertaken of 40 consecutive patients with recalcitrant tinea corporis/cruris/both who had taken systemic antifungal treatment and did not respond completely to therapy or had recurrent lesion within 1 month of stopping the therapy. Terbinafine, fluconazole, itraconazole, ketoconazole, amphotericin B, and voriconazole were the antifungals tested using broth microdilution assay for antifungal susceptibility testing of dermatophytes, and MIC50, 90 values were recorded.
KOH mount was positive in 18 (45%) patients, culture was positive in 28 (70%) patients. (35%) and (27.5%) were the predominant isolates. Overall, activity of terbinafine and itraconazole were significantly higher than the other drugs tested. For terbinafine, both and were inhibited at MIC of 0.125 μg/ml. Itraconazole-inhibited and at MIC of 0.0625 and 0.25 μg/ml, respectively. All isolates had reduced susceptibility to fluconazole.
While MIC seen were higher than western data, resistance (>1 μg/ml) to antifungals was not seen and probably may not be a cause of treatment failure. Possibly, treatment failure lies in the intricate host fungal interaction and virulence of species which help it to evade host immune response.
皮肤癣菌病是最常见的皮肤病之一,在很大程度上易于治疗。然而,近年来,这些感染对治疗变得顽固,这可能是由于抗真菌耐药性。
分析顽固性皮肤癣菌病患者的耐药模式。
对40例连续的顽固性体癣/股癣/两者皆有的患者进行横断面评估,这些患者接受了全身抗真菌治疗,但治疗未完全起效或在停止治疗后1个月内出现复发病变。使用肉汤微量稀释法对特比萘芬、氟康唑、伊曲康唑、酮康唑、两性霉素B和伏立康唑进行抗真菌药敏试验,以检测皮肤癣菌的药敏情况,并记录MIC50、90值。
18例(45%)患者的氢氧化钾涂片呈阳性,28例(70%)患者的培养呈阳性。(35%)和(27.5%)是主要分离株。总体而言,特比萘芬和伊曲康唑的活性明显高于其他测试药物。对于特比萘芬,和在0.125μg/ml的MIC时均受到抑制。伊曲康唑分别在0.0625和0.25μg/ml的MIC时抑制和。所有分离株对氟康唑的敏感性均降低。
虽然观察到的MIC高于西方数据,但未发现对抗真菌药的耐药性(>1μg/ml),这可能不是治疗失败的原因。治疗失败可能在于复杂的宿主-真菌相互作用以及有助于其逃避宿主免疫反应的菌种毒力。